rs111609623 - COX10-DT

Magnitude 2.0 · 1 study on file

Reported associations

• Improving lithium dose prediction using population pharmacokinetics and pharmacogenomics: a cohort genome-wide association study in Sweden. - The lancet. Psychiatry (2022) · Millischer V, Matheson GJ, Bergen SE, Coombes BJ, Ponzer K, Wikström F, Jagiello K, Lundberg M, Stenvinkel P, Biernacka JM, Breuer O, Martinsson L, Landén M, Backlund L, Lavebratt C, Schalling M · PubMed 35569502

  Lithium is the most effective treatment for bipolar disorder, resulting in strong suicide prevention effects. The therapeutic range of lithium, however, is narrow and treatment initiation requires individual titration to address inter-individual variability. We aimed to improve lithium dose prediction using clinical and genomic data. We performed a population pharmacokinetic study followed by a genome-wide association study (GWAS), including two clinical Swedish cohorts. Participants in cohort 1 were from specialised outpatient clinics at Huddinge Hospital, in Stockholm, Sweden, and participants in cohort 2 were identified using the Swedish National Quality Registry for Bipolar disorder (BipoläR). Patients who received a lithium dose corresponding to at least one tablet of lithium sulphat

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.